China SXT Pharmaceuticals Inventory 2018-2024 | SXTC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

China SXT Pharmaceuticals inventory from 2018 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

China SXT Pharmaceuticals inventory from 2018 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$74.8B
Chugai Pharmaceutical (CHGCY)	$70.2B
Takeda Pharmaceutical (TAK)	$41.1B
Sandoz Group AG (SDZNY)	$19.6B
Merck (MKKGY)	$18.8B
Astellas Pharma (ALPMY)	$17.3B
United Therapeutics (UTHR)	$16B
Neurocrine Biosciences (NBIX)	$14.5B
Summit Therapeutics (SMMT)	$14B
Shionogi (SGIOY)	$12.1B
Orion OYJ (ORINY)	$7.2B
Stevanato Group S.p.A (STVN)	$6.9B
Madrigal Pharmaceuticals (MDGL)	$6.4B
Corcept Therapeutics (CORT)	$5.8B
Hikma Pharmaceuticals Plc (HKMPF)	$5.5B
Grifols, S.A (GRFS)	$5B
Ionis Pharmaceuticals (IONS)	$5B
Crinetics Pharmaceuticals (CRNX)	$3.5B
Catalyst Pharmaceuticals (CPRX)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Recursion Pharmaceuticals (RXRX)	$2.6B
NewAmsterdam Pharma (NAMS)	$2.2B
Soleno Therapeutics (SLNO)	$2B
Centessa Pharmaceuticals (CNTA)	$2B
Hypermarcas (HYPMY)	$1.9B
Indivior (INDV)	$1.6B
BioCryst Pharmaceuticals (BCRX)	$1.5B
Evotec AG (EVO)	$1.5B
Dyne Therapeutics (DYN)	$1.4B
Xencor (XNCR)	$1.3B